Many recombinant immunogenic target-based vaccine formulations have been tested to protect against leishmaniasis at more or less advanced stages, such as LACK, A2, GP63, TSA, KMP-11, LiHyS, and LiHyp1, and a summary is provided in Table 1 (3–11). This evidence concerns the gene LMLN and leishmaniasis.